BlueRock Therapeutics is a new addition to the Toronto biotechnology neighborhood, launching its R & D hub in the MaRS ecosystem. The company is focused on innovative cell therapeutics produced from pluripotent stem cell technologies and state of the art bioengineering tools.
Dr. Robert Deans, a world respected stem cell biology industry veteran, will introduce colleagues and present BlueRock’s vision for their research and development plan. Dr. Deans will discuss harnessing stem cell biology to build new medicines; reaching for the horizon in regenerative medicine; and advancing innovative new technologies to build the future of stem cell therapeutics.
The presentation will include an overview of the cardiovascular programs that BlueRock Therapeutics will develop from technology originating from BlueRock scientific founder Gordon Keller and founding investigator Mike LaFlamme’s labs in collaboration with University Health Network (UHN); Centre for Commercialization of Regenerative Medicine (CCRM) and the McEwen Centre for Regenerative Medicine and with support from the Ontario Institute for Regenerative Medicine (OIRM). In addition, the clinical direction and status of BlueRock Therapeutics first-in-human program in neurodegenerative disease will be summarized and its future detailed.
- 11:30am-12:00 - Light lunch provided
- 12:00noon-12:10pm - Introductions
- 12:15pm-1:00pm - Presentation
- 1:00pm – 1:30pm - Networking